Sosei subsidiary co-founder quits for pastures new

Japanese GPCR medicines specialist Sosei Group (TYO Mothers Index: 4565) today announced that Dr Fiona Marshall has resigned from her position as executive vice president and chief scientific officer of Sosei to assume a senior role outside the company. She will leave Sosei at the end of February 2018.

“As a co-founder of Heptares [a wholly owned UK-based subsidiary of Sosei], I am very proud to have been associated with building a team of talented scientists over the past decade that has made many important breakthroughs in the field of GPCR stabilization and structure-based drug design, a unique technology that now underpins Sosei’s powerful drug discovery capability,” said Dr Marshall, adding: “With the team in excellent hands, I feel the time is right for me to move on to new challenges and I wish everyone at Sosei the best for what looks set to be an exciting future for the company.”

Peter Bains, chief executive of Sosei, added: “Fiona has been a pivotal figure in advancing the science of GPCR stabilization, and in creating Sosei StaR technology, a legacy that in time we believe will lead to the development of new and innovative medicines. Thanks to Fiona, we have built a deep pool of talented scientists who will continue to carry on our world-leading work in GPCR-focused drug discovery and development and execute on our vision to become a fully integrated global biotechnology company. The board and I express our sincere thanks to Fiona for her significant contributions to Sosei and wish her the very best in her exciting new role.”